Leman Biotech, represented by its co-founder Dr. Yugang Guo, R&D director Dr. Youjia Li, and Dr. Dudu Tong, recently visited Xiangxue Life Sciences, Ltd. The delegation was warmly welcomed by Mr. Lun Zeng, CEO, Dr. Haiping Gong, Vice President, Dr. Yingjie Huang, Chief Medical Officer, Dr. Shi Zhong, Chief Scientist, Dr. Hongjun Zheng, Deputy Director of R&D, and other R&D scientists from Xiangxue Life Sciences. The purpose of the visit was to foster exchange and collaboration between the two companies.
During the meeting , Dr. Yugang Guo praised the notable achievements of Xiangxue Life Sciences in the field of TCR-T cell therapy. He then presented Meta 10, the core technology of Leman Biotech, highlighting the superior performance of metabolism-enhanced immunnotherapy in addressing T-cell exhaustion in lymphoma and various solid tumors. Dr. Guo emphasized that Meta 10 effectively improves T-cell exhaustion and promotes the continuous expansion of tumor-specific T-cells within the tumor immune microenvironment, ultimately enhancing the overall response rate and efficacy of T-cell therapy. The participants engaged in discussion on this novel mechanism of metabolism-enhanced immunnotherapy.
Furthermore, Dr. Guo presentated insights into the development progress of Leman Biotech, including the layout and advancements of the R&D pipeline, as well as the latest clinical updates. The participants explored potential directions for future collaboration and identified key areas of mutual interest.
Xiangxue Life Sciences, a subsidiary of Xiangxue Pharmaceutical, currently leads the field of TCR-T cell drug development. It develops TAEST16001 (TCR-T cell) therapy for the treatment of advanced soft tissue sarcoma has entered a multi-center, open, single-arm, phase II clinical study, making it the first TCR-T cell therapeutic product in China to reach this stage of clinical development. This collaborative discussion between Leman Biotech and Xiangxue Life Sciences sets the stage for potential synergies in advancing innovative therapies for the benefit of patients.
